Last updated: 2026-09-07 18:43:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Silexion Therapeutics Corp. (SLXN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.35, with a market capitalization of $1.96M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.35 to $77.70. This page covers its latest market performance, valuation, price trends and company information.
$1.96M | |
$0.37 | |
$6,277.50 | |
$0.35 | |
$0.35 | |
202.34K | |
287.02K | |
-- | |
$77.70 | |
$0.35 | |
-- | |
-- |
Silexion Therapeutics Corp. (SLXN) last closed at $0.35 as of 2026-09-04 23:45:00, unchanged from the previous close of $0.35.
During the latest regular trading session, SLXN traded between $0.35 and $6,277.50, with a volume of 202.34K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Silexion Therapeutics Corp. (SLXN) moved from $0.36 to $0.35, representing a decline of 2.28% ($0.01).
The stock traded between $0.35 and $0.39 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 174.02 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.0%
SLXN is currently trading at $0.35, placing it 0.0% of the way from its 52-week low of $0.35 to its 52-week high of $77.70. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 13 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Silexion Therapeutics Corp. (SLXN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.